A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
Study sites
- AZ Maria Middelares, Gent
- CHU Sart Tilman, Liège
- Cliniques Universitaires St. Luc, Bruxelles
- Jessaziekenhuis, Hasselt
- UZ Antwerpen, Edegem
- UZ Gent, Gent
- UZ Leuven, Leuven
